Overview

Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5

Status:
Completed
Trial end date:
2018-12-14
Target enrollment:
Participant gender:
Summary
The objective of the study is to demonstrate the superiority of 0.1% octenidine mouthwash (Octenidin Mundspüllösung, OML) to placebo (PLAC) in the inhibition of plaque formation. The study will consist of a 14-day screening period and a 5-day treatment period.
Phase:
Phase 3
Details
Lead Sponsor:
Schülke & Mayr GmbH
Treatments:
Octenidine